The proteolytic conversion of plasminogen to plasmin effected by the plasminogen activators t-PA and u-PA is central to the process of fibrinolysis. These activators can be efficiently inhibited by plasminogen activator inhibitor PAI-1i,' which is the principal regulator of t-PA and u-PA activity and consequently of plasmin generation.
In human blood PAI-1 occurs in plasma23 and in platelets.45 PAI-1 in plasma is of low concentration but has relatively high specific activity; platelet PAI-1 is of low specific activity but accounts for around 93% of total circulating PAI-I in normal human blood. 6 The discovery of PAI-I in human blood has prompted the suggestion that In the liver generalised positive staining for PAI-I antigen was detected in hepatic parenchyma and in Kupffer cells. In the kidney positive staining was confined to a proportion of the cells present in glomeruli only (figure). It seemed likely that this represented specific staining of the mesangial cell population, as cultured mesangial cells were found to be a source of PAI-I antigen. Renal tubular epithelium did not show positive staining.
In several tissues positive staining was noted in cells of macrophage lineage. Thus alveolar macrophages (figure), splenic macrophages, microglial cells, and as indicated above, Kupffer cells, were identified as containing PAI-1.
Myocardial cells showed virtually no positive staining. Neural tissue from the brain and spinal cord showed uniformly negative staining, except for the neuroglial elements. These findings are consistent with the low concentrations ofPAI-1 in extracts ofheart and brain (table) .
Discussion
Considerable interest has centred on the possible role of PAI-1 in plasma and platelets in the control of intravascular events. Less is known of its contribution to extravascular processes; in particular, its distribution in human tissues has not been defined.
Our studies on extracted human tissues indicate that all organs examined contained PAI-I antigen, but that the concentrations in different tissues varied widely. Liver and spleen contained the highest quantities of antigen, while brain and myocardium contained only tiny amounts. Not only did antigen content vary but the functional activity of the PAI-1 varied independently of antigen. Thus the PAI-1 present in liver was ofhigher specific activity than that in spleen.
Tissue samples for analysis were obtained at necropsy from patients with a variety of dis- by any other process. Consistent with this, we have shown that a megakaryoblastic cell line, MEG-01, produces PAI-1. 20 A novel observation was the demonstration of PAI-i in neutrophil polymorphonuclear leucocytes in peripheral blood. Neutrophils have a central role in the early inflammatory response; they produce a number of active proteases including plasminogen activators. It may be that neutrophil PAI-1 assists in the regulation of local proteolysis in inflammatory processes, perhaps by exerting control of protein breakdown in inflammatory exudates.
In many tissues cells containing PAI-1 were of monocytoid lineage, the antigen being detected in splenic and alveolar macrophages, Kupf Clearly, PAI-1 is present in plasma, platelets, and vascular endothelium, the elements central to haemostasis. Our observations suggest this PAI-1 may also have a role in regulating extravascular proteolysis in inflammatory and other processes, as indicated by its presence in neutrophil polymorphs, macrophages, and smooth muscle cells. The presence of PAI-1, in quantity, in active form in liver suggests that hepatic PAI-1 may represent a source of plasma PAI-1, or that it participates ining in hepatic clearance ofplasma t-PA. The role of PAI-i in the extravascular compartment merits further study.
